In recent years, bulk drugs and intermediates ciprofloxacin Market Analysis - bulk drugs - the pharmaceutical industries

Quinolones Ketone Rapidly over the past decade the development of antibiotics is a class of antibiotics, broad spectrum, excellent in vitro activity, safety, big, small side effects, and including Pseudomonas aeruginosa, and Staphylococcus aureus intestinal bacteria, including Gram positive and negative bacteria have a strong bactericidal effect. Can be widely used in clinical respiratory tract infection, urinary tract infections, intestinal infections, intra-abdominal infections, gynecological infections, bone and joint infections and systemic treatment of serious infections than Cephalosporin Class of antibiotics, macrocyclic antibiotic, cheap.

Ciprofloxacin, levofloxacin, moxifloxacin is a listing of quinolones has been an excellent representative. Market capacity, Sell Volume has been ranked in the list of world's top-selling drugs, according to Datamonitor (DM) the company's research results are expected in 2009, fluoroquinolone antibiotics accounted for by the 2004 market share of 18% to 34% growth for the first antibiotic drugs. Today's world of terrorist incidents have occurred, the U.S. case of inhalation anthrax, resulting in another wave of ciprofloxacin hydrochloride, a sales peak, the recent United Nations procurement of 800 tons of ciprofloxacin bidding has attracted the concern of national pharmaceutical companies.

Currently, China, India, Germany (ciprofloxacin and moxifloxacin hydrochloride is Bayer's patent), Japan, the United States (Levofloxacin is the first pharmaceutical patent in Japan, the U.S. market by Johnson Sales) is the world's production and sales of fluoroquinolone antibiotics in most countries. Our fluoroquinolones have a certain scale of production in the international occupy 30% market share. Global market size of fluoroquinolones ciprofloxacin and levofloxacin mainly led by the sum of the two fluoroquinolones about 65% of global sales [1]. It is ciprofloxacin hydrochloride, Bayer, Germany and the United States in 2006 Schering-Plough's product sales of up to 755 million U.S. dollars in the world in the global prescription drug ranked 139. [2]

Quinolone drugs in India without patent protection, so no matter patent inside or outside the quinolone-patent drugs in India are in production. However, ciprofloxacin and levofloxacin and key Intermediate Are imported from China, India become China's largest ciprofloxacin (API) and intermediates Export Destination.

China more than 90% of ciprofloxacin (API) and intermediates manufacturing companies are concentrated in the Zhejiang region, according to surveys, over Zhejiang Jiashan, Zhejiang Medicine Co., Ltd. is the largest of ciprofloxacin (API) and The key intermediate manufacturer. Ciprofloxacin has two existing production process. A process which requires active substances used as intermediates of methyl amine compounds or cyclopropane carboxylic acid as starting materials to produce ciprofloxacin; also need to use a chelating Production cyproterone acetate as the starting raw materials to produce boric acid ciprofloxacin. Prudential up drug production in methyl amine compounds, cyclopropane carboxylic acid, boric acid ester Cyclopropyl three products that use these two processes for the production API Enterprise as a key intermediate to ciprofloxacin, which cyclopropane borate only the company's domestic production. According to different production processes to the industry average yield of conversion products, the production needs of 1.1 tons per ton of ciprofloxacin hydrochloride for methyl amine compounds or 0.9 tons of cyclopropane carboxylic acid, or 0.8 tons of cyclopropane acid ester, if the intermediate body converted into the amount of ciprofloxacin, the company's sales in 2007 and 2008, respectively 350 tons and 384 tons, or about 20% of domestic sales of ciprofloxacin.

I am an expert from firstaidsplint.com, while we provides the quality product, such as China leg splint , thumb splint Manufacturer, ,and more.